Newsroom

Retreatment With A Single TearCare™ Treatment Continues To Provide Relief For Patients With Dry Eye Disease

A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment for dry eye disease, according to a company news release.  The TearCare System is indicated for use in meibomian gland dysfunction (MGD), dry eye, and […]

read more +
Clinical Study Demonstrates Long Term IOP Reduction With The OMNI™ Surgical System Predicate Device (TRAB™360) In Micro-Invasive Glaucoma Surgery

A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI™ Surgical System’s Predicate Devices (TRAB™360) provides a favorable safety profile and substantial long-term reductions in both intraocular pressure (IOP) and IOP-lowering medications. Conducted by Steven Sarkisian, […]

read more +
First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI™ Surgical System for Multiple Micro-Invasive Glaucoma Surgery Procedures

MENLO PARK, Calif. – Sight Sciences today announced enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multi-center study to evaluate the safety and efficacy of the OMNI™ Surgical System in performing two sequential Micro-Invasive Glaucoma Surgery (MIGS) procedures – transluminal viscoelastic delivery and trabeculotomy. Subjects must have mild-to-moderate primary open angle glaucoma […]

read more +
Sight Sciences Announces Official Launches of TearCare™ and the Enhanced, Next Generation OMNI™ System

New Dry Eye and MIGS Entrants will be Prominently Featured in Product Demonstrations and Events at Upcoming Industry Shows MENLO PARK, Calif. – Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry – dry eye and glaucoma – today announced the official commercial launch of TearCare™ […]

read more +